This study will be conducted using retrospective health care claims data from insured migraine patients aged 18 to 64. Patients with a pharmacy claim for a combination treatment of sumatriptan and naproxen sodium (SumaRT/Nap) during the index period will be identified. If the SumaRT/Nap prescription is not preceeded by a single-entity triptan pharmacy claim in the 6-month, pre-index period, that patient will be included in the triptan-naive cohort. Propensity score matching will be used to identify migraine patients with new single-entity triptan claims as a comparator group. Patients with a pharmacy claim for a single-entity triptan in the 6-month, pre-index period and a pharmacy claim for SumaRT/Nap will be included in the triptan switch cohort. Propensity score matching will be used to identify patients with similar characteristics who switch to a new triptan as a comparator group.